一种新型非侵入性酶免疫测定法检测根除治疗后粪便中幽门螺杆菌的诊断准确性
Diagnostic accuracy of a new non-invasive enzyme immunoassay for detecting Helicobacter pylori in stools after eradication therapy.
作者信息
Ishihara S, Kaji T, Kawamura A, Rumi M A, Sato H, Okuyama T, Adachi K, Fukuda R, Watanabe M, Hashimoto T, Hirakawa K, Matsushima Y, Chiba T, Kinoshita Y
机构信息
Department of Internal Medicine II, Shimane Medical University Izumo, Japan.
出版信息
Aliment Pharmacol Ther. 2000 May;14(5):611-4. doi: 10.1046/j.1365-2036.2000.00736.x.
BACKGROUND
Helicobacter pylori eradication therapy has been commonly performed for patients with peptic ulcer. An inexpensive, reliable, non-invasive test would be useful for evaluation of the effectiveness of eradication therapy.
AIM
To evaluate the diagnostic potential of a new non-invasive enzyme immunoassay (HpSA) for H. pylori antigen in stools.
METHODS
A total of 112 peptic ulcer patients with H. pylori infection (82 male, 30 female; age range 22-81 years, mean 54 years) received a course of eradication therapy. Four weeks after the end of the therapy, stool samples were collected from all patients and tested using the HpSA. The diagnostic accuracy of the HpSA EIA was evaluated in comparison with the results of a 13C-urea breath test.
RESULTS
The diagnostic sensitivity of HpSA EIA after eradication therapy was 90%, the specificity 98%, the positive predictive value 82% and the negative predictive value 99%.
CONCLUSION
The HpSA stool test is potentially useful for the diagnosis of H. pylori infection 4 weeks after the end of eradication therapy.
背景
幽门螺杆菌根除治疗已普遍应用于消化性溃疡患者。一种廉价、可靠、非侵入性的检测方法对于评估根除治疗的效果将很有用。
目的
评估一种新的用于检测粪便中幽门螺杆菌抗原的非侵入性酶免疫测定法（HpSA）的诊断潜力。
方法
总共112例幽门螺杆菌感染的消化性溃疡患者（82例男性，30例女性；年龄范围22 - 81岁，平均54岁）接受了一个疗程的根除治疗。治疗结束4周后，收集所有患者的粪便样本并使用HpSA进行检测。将HpSA酶免疫测定法的诊断准确性与¹³C - 尿素呼气试验的结果进行比较评估。
结果
根除治疗后HpSA酶免疫测定法的诊断敏感性为90%，特异性为98%，阳性预测值为82%，阴性预测值为99%。
结论
HpSA粪便检测对于根除治疗结束4周后幽门螺杆菌感染的诊断可能有用。
Zotero 插件